Human Immunoglobulin for Intravenous Injection Market

The immunoglobulin combination was separated and extracted from normal human plasma by the low-temperature ethanol method, and refined through further processing and virus inactivation steps. This product is a complete, unmodified natural lgG antibody with a purity of up to 98%. It contains no preservatives and antibiotics and is intended for intravenous infusion. Compared with intramuscular gamma globulin, it has a faster effect and a significant effect. advantage.

Human Immunoglobulin for Intravenous Injection Market contains market size and forecasts of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) in global, including the following market information:

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) companies in 2021 (%)

The global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

1g/20ml Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) include Boya-Bio, Beijing Tiantan Biological Products, Hualan Bio, Guangdong Shuagnlin Bio-pharmacy, Weiguang Biological, Sinopharm, Shanghai RAAS, CTBB and Nanyue Biopharming. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Segment Percentages, by Type, 2021 (%)

1g/20ml

1.25g/25ml

2.5g/50ml

5g/100ml

10g/200ml

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Others

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) revenues share in global market, 2021 (%)

Key companies Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Boya-Bio

Beijing Tiantan Biological Products

Hualan Bio

Guangdong Shuagnlin Bio-pharmacy

Weiguang Biological

Sinopharm

Shanghai RAAS

CTBB

Nanyue Biopharming